|
11.1
During the seven-day baseline symptom documentation period
and the randomized double-blind study, patients will be
instructed to complete a daily questionnaire (Appendix
III) at roughly the same time each day to document severity
and frequency of hot flashes and side effects of treatment.
Similar data (Appendix
VI) will also be requested should the patient enter
the optional continuation study.
11.2
At the conclusion of the double-blind study, each patient
will be asked to document which treatment is preferred.
|